Over the last 7 days, the United States market has risen by 2.2%, and over the past year, it has climbed an impressive 32%, with earnings expected to grow by 15% per annum in the coming years. In this environment of robust growth, identifying high-growth tech stocks that can capitalize on these trends requires a focus on innovation, scalability, and strong financial health.
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
Super Micro Computer | 23.83% | 24.32% | ★★★★★★ |
Sarepta Therapeutics | 23.90% | 42.65% | ★★★★★★ |
Clene | 78.50% | 60.16% | ★★★★★★ |
TG Therapeutics | 34.66% | 56.48% | ★★★★★★ |
Alkami Technology | 21.89% | 98.60% | ★★★★★★ |
Alnylam Pharmaceuticals | 22.45% | 70.66% | ★★★★★★ |
Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
Blueprint Medicines | 25.47% | 68.62% | ★★★★★★ |
Seagen | 22.57% | 71.80% | ★★★★★★ |
ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.
Here's a peek at a few of the choices from the screener.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: BeiGene, Ltd. is an oncology-focused company involved in the discovery and development of cancer treatments across the United States, China, Europe, and other international markets with a market capitalization of approximately $20.24 billion.
Operations: BeiGene generates revenue primarily from its pharmaceutical products, amounting to CN¥23.51 billion. The company is focused on oncology, developing treatments for cancer patients across multiple regions.
BeiGene, amidst a challenging landscape marked by a net loss of CNY 3.69 billion for the first nine months of 2024, continues to innovate in the oncology sector with significant advancements in its pipeline. The company’s commitment to research and development is underscored by its recent positive CHMP opinions for TEVIMBRA in various cancer treatments, reflecting a strategic focus on expanding indications which could enhance future revenue streams. Despite these advances and a robust 19.5% year-over-year revenue growth, BeiGene's earnings trajectory faces pressures with an anticipated annual earnings growth rate of 73.2%. This juxtaposition highlights the firm's ongoing investment in transformative cancer therapies while navigating financial volatility inherent in high-stakes biotech endeavors.
Understand BeiGene's track record by examining our Past report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Concentrix Corporation provides technology-infused customer experience solutions on a global scale and has a market capitalization of approximately $2.83 billion.
Operations: The company generates revenue primarily from its Software & Programming segment, amounting to $9.40 billion.
Concentrix, navigating a complex tech landscape, has demonstrated resilience with a projected annual earnings growth of 50.9%, significantly outpacing the broader U.S. market's average of 15.4%. This robust growth trajectory is underpinned by strategic investments in R&D, which have consistently accounted for a substantial portion of revenue—evidence of the firm’s commitment to innovation and competitive differentiation in business services. Despite facing challenges like a recent one-off loss of $116.2 million affecting financials, Concentrix's forward-looking initiatives signal strong future prospects, particularly as it leverages AI trends discussed at recent industry events to enhance service offerings and client engagement strategies.
Gain insights into Concentrix's historical performance by reviewing our past performance report.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: DigitalOcean Holdings, Inc. operates a cloud computing platform with a global presence across North America, Europe, and Asia, and has a market capitalization of approximately $3.65 billion.
Operations: DigitalOcean Holdings generates revenue primarily from its Internet Software & Services segment, amounting to $756.56 million. The company leverages its cloud computing platform to serve a global customer base across various regions.
DigitalOcean Holdings, Inc. has shown a promising trajectory with recent product advancements and robust financial performance. The company's introduction of scalable storage for Managed MongoDB and dedicated Bare Metal GPUs underscores its commitment to innovation, catering to the growing demands of AI/ML workloads. Financially, DigitalOcean reported a significant increase in quarterly sales from $177.06 million to $198.48 million year-over-year and expects annual revenues between $775 million and $777 million. This growth is supported by an 18.2% forecast in earnings growth per year, outpacing the broader market's average of 15.4%. Additionally, R&D investments remain a cornerstone of their strategy, ensuring sustained technological advancement and competitive edge in the cloud services sector.
Assess DigitalOcean Holdings' past performance with our detailed historical performance reports.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com